AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: NANCY GONDO
Most generic drug makers aim to make an exact copy of a branded medicine. American Pharmaceutical Partners wants to take that process a step further.
Begun in 1996, the young firm tries to make generic drugs even better and more popular by tweaking the formulas to leave out side effects. Judging by its results, the strategy seems to be working.
Late September, American announced positive initial results from late-stage tests of Abraxane, its version of Bristol-Myers Squibb's Taxol breast cancer drug. In 2002, Bristol-Myers did $857 million in sales of the blockbuster drug.
What's the difference between the two? American's Abraxane lacks cremophor, a solvent thought to be toxic. In some cases, this solvent can lower patients' blood counts, cause severe allergic reactions or even result in death.
As if that's not bad enough, cremophor may interfere with Taxol's potency, says American CEO Patrick Soon-Shiong.
"You then have the worst of all worlds in the highest toxicity and lowest efficacy because of cremophor," Soon-Shiong said. "That is what Abraxane is trying to address."